Research advances in the role of coagulation factors in liver fibrosis

Li SuXin; Li LuHao; Dang XiaoWei

doi:10.3969/j.issn.1001-5256.2018.07.039

Issue 7

Jul. 2018

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2018 > 34(7): 1547-1550

PDF( 1538 KB)

Research advances in the role of coagulation factors in liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2018.07.039

Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of Zhengzhou University

Research funding:

Received Date: 2018-01-22
Published Date: 2018-07-20

Abstract

Abstract

Present studies on organ fibrosis including liver fibrosis show that coagulation factors and inflammatory response promote the progression of organ fibrosis, which makes people to be aware of the fact that the change in coagulation factors is not only a secondary event to liver fibrosis, and coagulation factors also play an important role in the development and progression of liver fibrosis. Recent studies have shown that most of the coagulation factors with thrombotic tendency promote liver fibrosis, while those with bleeding or hemolytic tendency inhibit liver fibrosis. Anticoagulant therapy can significantly improve or alleviate liver fibrosis, and therefore, it may provide a direction for the treatment of liver fibrosis in future. This article reviews the research advances in the role of coagulation factors in liver fibrosis.
- liver cirrhosis,
- coagulation factors,
- inflammation,
- review

FullText(HTML)

References(35)

References

[1]SAXENA NK, ANANIA FA.Adipocytokines and hepatic fibrosis[J].Trends Endocrinol Metab, 2015, 26 (3) :153-161.

[2]LEONARDI F, MARIA N, VILLA E.Anticoagulation in cirrhosis:A new paradigm?[J].Clin Mol Hepatol, 2017, 23 (1) :13-21.

[3]WANLESS IR, WONG F, BLENDIS LM, et al.Hepatic and portal vein thrombosis in cirrhosis:Possible role in the development of parenchymal extinction and portal hypertension[J].Hepatology, 1995, 21 (5) :1238-1247.

[4]JAIRATH V, BURROUGHS AK.Anticoagulation in patients with liver cirrhosis:Complication or therapeutic opportunity?[J].Gut, 2013, 62 (4) :479-482.

[5]SEKI E, SCHWABE RF.Hepatic inflammation and fibrosis:Functional links and key pathways[J].Hepatology, 2015, 61 (3) :1066-1079.

[6]HELLEBRAND C, WILKENS G, KOHL J, et al.Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans[J].Nat Genet, 2005, 37 (8) :835-843.

[7]TRIPODI A, PRIMIGNANI M, CHANTARANGKUL V, et al.An imbalance of pro-vs anti-coagulation factors in plasma from patients with cirrhosis[J].Gastroenterology, 2009, 137 (6) :2105-2111.

[8]SIMONETTO DA, YANG HY, YIN M, et al.Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces[J].Hepatology, 2015, 61 (2) :648-659.

[9]CHAMBERS RC.Abnormal wound healing responses in pulmonary fibrosis:Focus on coagulation signalling[J].Eur Respir Rev, 2008, 17 (109) :130-137.

[10]OWENS AP, MACKMAN N.Tissue factor and thrombosis:The clot starts here[J].Thromb Haemost, 2010, 104 (3) :432-439.

[11]RAUTOU PE, TATSUMI K, ANTONIAK S, et al.Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury[J].J Hepatol, 2016, 64 (1) :53-59.

[12]MOCHIDA S, ARAI S, YAMANOBE F, et al.Anticoagulant targeting for hepatic sinusoidal walls in prevention of hypercoagulopathy in cold preserved rat livers[J].Transplant Proc, 1998, 30 (1) :45-48.

[13]CALVARUSO V, MAIMONE S, GATT A, et al.Coagulation and fibrosis in chronic liver disease[J].Gut, 2008, 57 (12) :1722-1727.

[14]CAMERER E, HUANG W, COUGHLIN SR.Tissue factor-and factor X-dependent activation of protease-activated receptor 2 by factor VIIa[J].Proc Natl Acad Sci U S A, 2000, 97 (10) :5255-5260.

[15]NAULT R, FADER KA, KOPEC AK, et al.From the cover:Coagulation-driven hepatic fibrosis requires protease activated receptor-1 (PAR-1) in a mouse model of TCDD-elicited steatohepatitis[J].Toxicol Sci, 2016, 154 (2) :381-391.

[16]KITASATO L, YAMAOKA-TOJO M, HASHIKATA T, et al.Factor Xa in mouse fibroblasts may induce fibrosis more than thrombin[J].Int Heart J, 2014, 55 (4) :357-361.

[17]HOWELL DCJ, GOLDSACK NR, MARSHALL RP, et al.Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis[J].Am J Pathol, 2001, 159 (4) :1383-1395.

[18]BORENSZTAJN K, von der THUSEN, JAN H, et al.The coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis:A multifaceted paradigm[J].J Cell Mol Med, 2010, 14 (1-2) :143-153.

[19]FIORUCCI S, ANTONELLI E, DISTRUTTI E, et al.PAR1 antagonism protects against experimental liver fibrosis.Role of proteinase receptors in stellate cell activation[J].Hepatology, 2004, 39 (2) :365-375.

[20]RUPPERT C, MARKART P, WYGRECKA M, et al.Role of coagulation and fibrinolysis in lung and renal fibrosis[J].Hamostaseologie, 2008, 28 (1-2) :30-36.

[21]ATKINSON JM, PULLEN N, Da SILVA-LODGE M, et al.Inhibition of thrombin-activated fibrinolysis inhibitor increases survival in experimental kidney fibrosis[J].J Am Soc Nephrol, 2015, 26 (8) :1925-1937.

[22]MERCER PF, CHAMBERS RC.Coagulation and coagulation sig-nalling in fibrosis[J].Biochim Biophys Acta, 2013, 1832 (7) :1018-1027.

[23]HOEKSTRA J, GUIMARAES AH, LEEBEEK FW, et al.Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome[J].Blood, 2010, 115 (2) :388-395.

[24]BORENSZTAJN K, CONG L, FRANCOIS C, et al.Coagulation factor IX deficiency does not afford protection from pulmonary fibrosis in the experimental murine bleomycin model[J].Eur Respir J, 2012, 40:3670.

[25]WILBERDING JA, PLOPLIS VA, MCLENNAN I, et al.Development of pulmonary fibrosis in fibrinogen-deficient mice[J].Ann N Y Acad Sci, 2001, 936 (1) :542-548.

[26]RAMACHANDRAN R, NOORBAKHSH F, DEFEA K, et al.Targeting proteinase-activated receptors:Therapeutic potential and challenges[J].Nat Rev Drug Discov, 2012, 11 (1) :69-86.

[27]CHAMBERS RC.Role of coagulation cascade proteases in lung repair and fibrosis[J].Eur Respir J, 2003, 22 (44) :33-35.

[28]MARIA ME, MAR A TM, ANTONIO JRA, et al.Inflammatory status in human hepatic cirrhosis[J].World J Gastroenterol, 2015, 21 (41) :11522-11541.

[29]SENZOLO M, M SARTORI T, ROSSETTO V, et al.Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis[J].Liver Int, 2012, 32 (6) :919-927.

[30]CERINI F, VILASECA M, LAFOZ E, et al.Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats[J].J Hepatol, 2016, 64 (4) :834-842.

[31]WANG BY, ZHAO W, NIU XM, et al.Mechanism of action of Yiqi Huoxue Recipe in regulating autophagy and reversing liver fi-brosis[J].Chin J Hepatol, 2017, 25 (5) :365-370. (in Chinese) 王宝玉, 赵文, 牛学敏, 等.益气活血方调节自噬及逆转肝纤维化机制的研究[J].中华肝脏病杂志, 2017, 25 (5) :365-370.

[32]XIE XC, LIU MH, ZHAO SH, et al.Assessment of therapeutic effect of nuemu pill in the hepatitis-B liver fibrosis[J].J Changchun Univ Chin Med, 2016, 32 (1) :123-125. (in Chinese) 谢湘春, 刘明晖, 赵树华, 等.疟母丸治疗乙型肝炎肝纤维化的效果[J].长春中医药大学学报, 2016, 32 (1) :123-125.

[33]LI WC, ZHANG JS, ZHU HG, et al.Effect of low anticoagulative activity heparin on the growth of rat hepatic stellate cells[J].J Zhengzhou Univ:Med Sci, 2007, 42 (3) :451-453. (in Chinese) 李文才, 张锦生, 朱虹光, 等.低抗凝肝素对大鼠肝星状细胞生长的影响[J].郑州大学学报:医学版, 2007, 42 (3) :451-453.

[34]LI CJ, YANG ZH, SHI XL, et al.Effects of aspirin and enoxaparin in a rat model of liver fibrosis[J].World J Gastroenterol, 2017, 23 (35) :6412-6419.

[35]YAN YS, GUAN CG, DU SS, et al.Effects of enzymatically depolymerized low molecular weight heparins on CCl4-induced liver fibrosis[J].Front Pharmacol, 2017, 8:514.

Relative Articles

[1]	Yunchong WU, Yanyan YANG, Chuan LI, Xiaohuan WU, Shide LIN. Role of inflammatory cytokines in disorder of glucose metabolism in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1886-1890. doi: 10.12449/JCH240926
[2]	Zhan ZENG, Yuanjiao GAO, Xiaoyue BI, Fengxin CHEN, Wen DENG, Tingting JIANG, Yanjie LIN, Liu YANG, Minghui LI, Yao XIE. Value of HBsAg level in predicting liver inflammation in patients with HBeAg-positive chronic hepatitis B virus infection and normal alanine aminotransferase[J]. Journal of Clinical Hepatology, 2022, 38(5): 1030-1034. doi: 10.3969/j.issn.1001-5256.2022.05.011
[3]	Huaqian XU, Xue LI, Shanhong TANG. Research advances in the role of inflammatory response and related treatment strategies in acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2022, 38(8): 1927-1930. doi: 10.3969/j.issn.1001-5256.2022.08.041
[4]	Ting LI, Huabao LIU, Wenyan HU, Chunyan RAO. Role of inflammation in hepatic fibrosis[J]. Journal of Clinical Hepatology, 2022, 38(10): 2368-2372. doi: 10.3969/j.issn.1001-5256.2022.10.032
[5]	Xinlan ZHOU, Xin MA, Yanbing WANG, Xiufen LI, Dan HUANG, Wei LU, Zhanqing ZHANG, Rongrong DING. Value of aspartate aminotransferase-to-platelet ratio index, fibrosis-4, and gamma-glutamyl transpeptidase-to-platelet ratio in diagnosis of liver inflammation grade in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(9): 2066-2070. doi: 10.3969/j.issn.1001-5256.2021.09.013
[6]	Yao LI, Jingchao WANG, Jiaqi YUAN, Hao WEN, Ying ZHOU, Haining FAN, Zhixin WANG. Influence of endoplasmic reticulum stress on the secretion of some inflammatory mediators in hepatic alveolar echinococcosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 131-134. doi: 10.3969/j.issn.1001-5256.2021.01.026
[7]	Wang TingShuai, Wang Na, Zhang RongZhen, Wang MingGang, Huang ShaoDong, Ma YuZhen, Wu Cong, Mao DeWen. Role of immune response and inflammatory injury in the pathogenesis of liver failure[J]. Journal of Clinical Hepatology, 2020, 36(6): 1415-1419. doi: 10.3969/j.issn.1001-5256.2020.06.050
[8]	Yin JinPing, Yue ZiChen, Zhuo ShaoYuan. STAT3: A key molecule in the progression of liver cancer mediated by chronic inflammation[J]. Journal of Clinical Hepatology, 2020, 36(4): 948-952. doi: 10.3969/j.issn.1001-5256.2020.04.054
[9]	Guo Yan, Huang Li, Yang GuoChao, Liu Shan, Du LinNa, Wang MinJuan. Association between nonalcoholic fatty liver disease and dietary inflammation index and its practical significance[J]. Journal of Clinical Hepatology, 2019, 35(10): 2324-2326. doi: 10.3969/j.issn.1001-5256.2019.10.042
[10]	Liu Li, Li JunYi, Du YingRong, Huang HongLi, Luo Yu, Li HuiMin, Li WeiKun, Wang Lin, Liu ChunYun. Influencing factors for liver inflammation grade and fibrosis degree in patients with low-level HBV DNA[J]. Journal of Clinical Hepatology, 2019, 35(5): 982-986. doi: 10.3969/j.issn.1001-5256.2019.05.010
[11]	He Yang, Su YaRong, Han ZiYan. Current status of research on primary and secondary risk factors for esophagogastric variceal rebleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(7): 1555-1559. doi: 10.3969/j.issn.1001-5256.2018.07.041
[12]	Wang WanQin, Wen MaoYao, Fan XiaoLi, Shen Yi, Yang XiaoXue, Yang Li. Research advances in liver cirrhosis complicated by portal vein thrombosis[J]. Journal of Clinical Hepatology, 2016, 32(7): 1409-1412. doi: 10.3969/j.issn.1001-5256.2016.07.045
[13]	Zhang XinTong, Qi XingShun, Gao Fan, Guo XiaoZhong. Research advances in venous thromboembolism in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(10): 2004-2006. doi: 10.3969/j.issn.1001-5256.2016.10.043
[14]	Li Qiang, Huang YuXian, Chen Liang. Simple serum markers for significant liver inflammation in chronic hepatitis B patients with an alanine aminotransferase level lower than 2 times upper limit of normal[J]. Journal of Clinical Hepatology, 2016, 32(6): 1125-1129. doi: 10.3969/j.issn.1001-5256.2016.06.021
[15]	Ding Jie, Wang Liang, Li Juan, Kong Yin, Zhao Rui, He JingJing, Li GuangMing, Wang JuanXia, Zhang LingYi. Changes in serum asymmetric dimethylarginine levels in progression of liver inflammation in an experimental rat model of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2016, 32(1): 148-151. doi: 10.3969/j.issn.1001-5256.2016.01.029
[16]	Zhu JuanJuan, Cheng MingLiang, Zhao XueKe. Role of liver immunological inflammation in development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2016, 32(3): 570-573. doi: 10.3969/j.issn.1001-5256.2016.03.038
[17]	Wu YuJing, Guo JinSheng. Hepatic stellate cells,Toll-like receptor 4 signaling pathway,and inflammatory fibrotic microenvironment in the development of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(6): 876-879. doi: 10.3969/j.issn.1001-5256.2015.06.012
[18]	Wang JingYun, Sun Jing, Gao YanHang. Research advances in liver cirrhosis complicated by bacteremia[J]. Journal of Clinical Hepatology, 2014, 30(7): 683-686. doi: 10.3969/j.issn.1001-5256.2014.07.030
[19]	Dong HongYun, Zhao GuiMing, Li Ying. Study on the relationship between inflammation activity in the liver tissues and expression of HBcAg in patients with chronic hepatits B[J]. Journal of Clinical Hepatology, 2007, 23(1): 13-14.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	袁会成，万学娜，胥少华，赵良存，杨凯. 基于网络药理学和分子对接研究金丹健肝胶囊治疗肝纤维化的作用机制. 中国热带医学. 2023(08): 863-869 .
2.	区永光，夏汝年，梁灵. 凝血指标在肝纤维化进展中的作用分析. 中国医学创新. 2021(07): 130-133 .
3.	王亚刚，胡国信. 同型半胱氨酸在肝纤维化和肝硬化发展中的作用. 临床肝胆病杂志. 2020(05): 1146-1149 . 本站查看

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1376) PDF downloads(354)

Research advances in the role of coagulation factors in liver fibrosis

DOI: 10.3969/j.issn.1001-5256.2018.07.039